TriSalus Life Sciences (TLSI) CFO adds 3,657 shares in open-market buy

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported an open-market purchase of 3,657 shares of common stock at $4.10 per share. Following this transaction, his directly owned stake increased to 268,657 shares, signaling additional personal capital committed to the company.

Insider Trade Summary

Net Buyer: 3,657 shares ($14,994)

Net Buy 1 txn

Insider Patience David

Role Chief Financial Officer

Bought 3,657 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	3,657	$4.10	$15K

Holdings After Transaction: Common Stock — 268,657 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patience David

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		P		3,657	A	$4.1	268,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ David Patience	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TriSalus (TLSI) report for its CFO?

TriSalus reported that Chief Financial Officer David Patience bought 3,657 shares of common stock in an open-market transaction at $4.10 per share, increasing his direct holdings to 268,657 shares as of the reported Form 4 date.

How many TriSalus (TLSI) shares does the CFO own after this Form 4?

After the reported transaction, Chief Financial Officer David Patience directly owns 268,657 shares of TriSalus common stock. This total reflects the addition of 3,657 shares purchased in the open market at $4.10 per share in the reported filing.

Was the TriSalus (TLSI) CFO transaction a purchase or a sale?

The transaction was a purchase. Chief Financial Officer David Patience acquired 3,657 shares of TriSalus common stock in an open-market buy at $4.10 per share, increasing his directly owned stake as shown in the Form 4 filing.

What price did the TriSalus (TLSI) CFO pay per share in the Form 4 trade?

Chief Financial Officer David Patience paid $4.10 per share for 3,657 shares of TriSalus common stock. This open-market purchase raised his direct ownership to 268,657 shares, according to the details reported in the insider Form 4 filing.

Who is the insider involved in the latest TriSalus (TLSI) Form 4 filing?

The insider is David Patience, the Chief Financial Officer of TriSalus Life Sciences, Inc. He reported an open-market purchase of 3,657 common shares at $4.10 each, bringing his directly held position to 268,657 shares following the transaction.